Cenexel Act — research payments reported

By program year

4 rows

Year	Kind	Amount	Payments
2025	Research	$7,390,656	10
2024	Research	$9,465,809	7
2023	Research	$4,519,794	6
2022	Research	$528,963	1

Breakdown

Who paid Research payments · program years 2022–2025

E.R. Squibb & Sons, L.L.C. $20,728,359 15 payments
Celgene Corporation $859,422 4 payments
AstraZeneca Pharmaceuticals LP $314,282 4 payments
Amgen Inc. $3,159 1 payment

Studies the money was for Research payments · program years 2022–2025

A Study to Evaluate the Safety, Tolerability, and Drug Levels of Orally Administered BMS-986368 in Healthy Participants, Healthy Elderly Participants, and Healthy Participants of Japanese Ethnicity $6,296,945 2 payments
An Open-label, Randomized, 2-Part, 4-Period, 2-Sequence, Fully Replicated Crossover Study to Assess the Comparative Bioavailability of BMS-986278 To-be-marketed Formulation Compared to the Phase 3 Clinical Trial Formulation in Healthy Participants $3,304,409 2 payments
A 2-Part, Phase 1, Randomized, Double-bind, Placebo-controlled Study to Assess the Safety, Tolerability and Pharmacokinetics of Multiple Doses of BMS-986510 Administered as Immediate-Release Capsules or Dual-burst Capsules in Healthy Adult and Elderly Japanese Participants (Part 1) and an Open-label Study to Assess the Effect of Omeprazole on the Pharmacokinetics of BMS-986510 Administered as Dual-burst Capsules in Healthy Elderly Participants (Part 2) $2,862,400 1 payment
Ph I PK study of KarXT in HV young and elderly (Japan) $2,733,385 1 payment
Relative BA (New Formulation) - A Phase 1, Open-label, Randomized, Parallel-group, Single dose Study to Assess the Relative Bioavailability of a New BMS-986419 Immediate-release Tablet Formulation Compared to a Reference Enteric Capsule (Delayed-release) $2,210,427 2 payments
Phase I Dani PK Bridging Study (Japan) $1,246,079 1 payment
Relative BA - A Phase 1, Open-label, Randomized, Single-dose, 3-Period, 3-Sequence Crossover Study to Assess the Relative Bioavailability of the Intended Commercial Formulation Versus the Previous MyoKardia Formulation of Danicamtiv and to Assess the Effe $1,026,353 1 payment
A Randomized, Open-Label, Single Dose Study Assessing thePharmacokinetics, Tolerability and absolute bioavailability of subcutaneous injection of BMS-986446, an Anti-MTBR Tau Monoclonal Antibody, in Normal Healthy Participants $984,074 1 payment
Phase 1 DDI (MTX/SSZ) Repeat of CP-002 $829,042 3 payments
A Phase 2a Randomized, Observer-blind, Placebo-controlled, Dosage Optimization, Multi-center Clinical Trial to Evaluate the Safety and Immunogenicity of IVX-A12, a Respiratory Syncytial Virus and Human Metapneumovirus Bivalent Combination Virus-like Particle Protein Subunit Vaccine, in Adults 60 to 85 Years of Age $229,795 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.